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Table 1. Association between TM6SF2 rs58542926 variant and NAFLD.
Genotype count Statistical analysis*
Genotype CC CT TT Unconditioned Condition on rs738409 Condition on rs2228603
Control 333 33 0 OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Case 302 65 0 2.2 (1.4-3.4) 0.0007 2.3 (1.4-3.6) 0.0004 2.1 (1.4-3.4) 0.001
⁄Associations were tested using logistic regression with adjustment for age, sex, BMI and status of diabetes.
OR, odds ratio; CI, conﬁdence interval.
 These authors contributed equally to this work.
JOURNAL OF HEPATOLOGYIs it worthy of switching to PegIFN alfa-2a in patients achieving
virological suppression with entecavir?
To the Editor:
We read with great interest the article ‘‘Switching from entecavir
to PegIFN alfa-2a in patients with HBeAg positive chronic hepati-
tis B: A randomized open-label trial (OSST trial)’’ [1]. This elegant
study assessed the rates of HBeAg seroconversion and HBsAg loss
in patients with well-controlled HBV DNA replication and serum
HBeAg <100 PEIU/ml on long-term entecavir (ETV) therapy after
switching to a ﬁnite course of PegIFN alfa-2a. Qin Ning et al. [1]
demonstrated that switching to a ﬁnite course of PegIFN alfa-2a
signiﬁcantly increased rates of HBeAg seroconversion and
HBsAg loss and concluded this is a potential alternative to indeﬁ-
nite nucleos(t)ide analogue (NA) therapy.
Many chronic hepatitis B patients are treated with ETV in
China. Some of them hope to stop this inﬁnite treatment if a ﬁnite
course of treatment can give similar or better outcomes with a
reasonable cost and minimal adverse effects. In Shenzhen,
patients receiving sequential therapy with NA and PegIFN are
not rare. However, there are several concerns about this article
and its approach. First, the absolute difference in HBeAg serocon-
version rate was only 8.8%. In other words, the number to treat for
one HBeAg seroconversion is 11. All these patients have to suffer
the adverse effects of PegIFN. It is well known that hepatic decom-
pensation and even death has been reported during IFN treat-
ment. We should also pay special attention to the adverse effect
of stopping of ETV. Hepatic decompensation or liver failure was
not recorded in the study given the sample size. Recently, one of
my patients developed acute on chronic liver failure during
PegIFN treatment after stopping ETV and adefovir (ADV) which
was reported on in a local hepatology meeting. The effect of an
overlapping period of ETV and PegIFN on safety and efﬁcacyJournal of Hepatology 2015 vol. 62 j 1438–1454 1439
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In summary, as clinicians, after weighing the pros and cons,
we do not think it is worthy of switching to PegIFN in patients
achieving virological suppression with ETV, except if the patient
refuse a long-term treatment.
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Center, Kansas City, KS, United Statesremains unclear. Second, the other endpoints of HBV DNA sup-
pression <1000 copies/ml and ALT normalization after 48 weeks
of PegIFN treatment was unsatisfactory. These results might be
worse after withdrawal of PegIFN therapy. Most of the patients
had to resume ETV treatment, which is terrible news for a doctor
to have to deliver to patients after a long course of PegIFN therapy.
Third, sustained and profound viral suppression is the main goal
of treatment. The ﬂuctuation of ALT and HBV DNA in the sequen-
tial therapymaymimic the phenomena of viral resistance to NA. It
has been reported that treatment related viral resistance blunts
histologic responses [2] and increases the rate of hepatocellular
carcinoma (HCC) even if rescue therapy is given [3]. Fourth, the
cost of treatment should also be considered. The per capita dispos-
able income is 18,311 RMB (2982 USD) in China 2013. The cost
of 48 weeks of PegIFN treatment is about 50,000 RMB
(8143 USD). Most of the treatment-naïve patients in China
may ﬁnd this treatment unaffordable. The cost of 48 weeks ETV
is only one ﬁfth of that. Fifth, the causative agent has not been
identiﬁed in this randomized controlled study. The treatment
arm underwent ETV withdrawal and PegIFN. Withdrawal of ADV
after 4–5 years of therapy has been shown to result in 39%
HBsAg loss in selected HBeAg negative patients [4]. To date, there
has never been a parallel study in HBeAg positive patients, and
there has never been a randomized control trial with PegIFN that
involves a control armwith NAwithdrawal only.We are anxiously
waiting for such a study, we can no longer make the assumption
that the treatment effect is entirely due to PegIFN. The correlation
between early ALT elevation after withdrawal of ETV with HBeAg
seroconversion and HBsAg loss supports this hypothesis. Finally,
the beneﬁt of HBeAg seroconversion should not be over
emphasized. HBeAg seroconversion has long been regarded as
an important treatment endpoint in hepatitis B therapy.
However, with the prevalence of pre-core or core mutation HBV
infection, HBeAg seroconversion is no longer an ideal endpoint.
Recently, Jessica Liu et al. demonstrated that HBV DNA seroclear-
ance, during the course of chronic hepatitis B, is the most signiﬁ-
cant factor in reducing risk for future HCC and HBeAg
seroclearance will not reduce future HCC further [5].
Combination endpoint with HBeAg seroconversion and HBV
DNA <1000 copies/ml may be more reasonable as the primary
endpoint. We do not know if the signiﬁcant difference between
the two cohorts was lost with this endpoint.
Letters to the EditorRepeated transarterial chemoembolization: An overﬁtting effort?
To the Editor:
We read with great interest the article by Adhoute et al. pub-
lished in Journal of Hepatology [1]. The authors developed a point
score system, the ABCR [standing for Alpha-fetoprotein (AFP),
Barcelona Clinic Liver Cancer (BCLC), Child-Pugh and Response],
to assist in the decision making on whether to retreat hep-
atocellular carcinoma (HCC) patients with multiple transarterial
chemoembolization (TACE) sessions. The study population con-
sisted of HCC patients treated with repeated consecutive TACE
sessions and the resulting signiﬁcant parameters from regression
analysis were used to build the score. In this way, the authors
differentiated three groups with different survival. The score
was consistently validated in training and conﬁrmatory cohorts
and a higher ABCR score after the ﬁrst TACE course was found
to be associated with patients at poorer prognosis who may not
beneﬁt from further TACE sessions.
Current guidelines do not specify the criteria for repeating
TACE and the correct number of repeated procedures to under-
take, hence the paper by Adhoute et al. is certainly of interest.
However, it should be noted that patients in more advanced
BCLC stage and with higher baseline AFP levels, namely those
requiring further treatment repetitions are considered less likely
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